13 Jan 2022
AstraZeneca Announces U.S. Decision to Purchase Extra 500,000 Evusheld Doses
The Index Today
AstraZeneca on Wednesday unveiled the U.S. government’s plans to buy an extra 500,000 doses of its Evusheld which can be used to prevent COVID-19 among the public prior to exposure.
Evusheld has a demonstrated ability to protect against the Omicron variant of the coronavirus through its neutralizing property. It is has proven to be one of the most effective solutions for people with weak immune systems who might otherwise experience more difficulty in fighting the virus.
As the sole antibody therapy authorized in the country, the doses are said to arrive in the U.S. within Q1 of 2022, adding to a previous batch of 700,000 Evusheld doses.